| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
DNA-PK-IN-13 exhibited the best antiproliferative activity in Jurkat (T lymphoma) cells with IC50 = 0.6 μM[1]. DNA-PK-IN-13 (0.1-40 μM; 10 minutes) concentration-dependently reduced the expression level of γH2A.X in Jurkat cells and HepG2 cells[1]. The combination of DNA-PK-IN-13 (1 μM; 24 hours) and doxorubicin (HY-15142A) (0.1 μM) significantly reduced the proportion of S phase of Jurkat cell cycle and increased the proportion of G2/M phase[1].
|
|---|---|
| ln Vivo |
DNA-PK-IN-13 has good oral bioavailability (F = 31.8%)[1].
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: HepG2 cells, Jurkat Tested Concentrations: 0.1; 0.5; 5; 10; 20; 40μM Incubation Duration: 10min Experimental Results: Concentration-dependently decreased the expression level of γH2A.X in Jurkat cells and HepG2 cells. DNA-PK-IN-13 can affect the production of γH2A.X and thus inhibit DNA damage repair. Cell Cycle Analysis[1] Cell Types: Jurkat Tested Concentrations: 1μM; Dox 0.1μM Incubation Duration: 24h Experimental Results: DNA-PK-IN-13 alone did not demonstrate statistically significant differences in the cell cycle. However, when combined with doxorubicin, DNA-PK-IN-13 influenced the cell cycle, contributing to cell death. |
| Animal Protocol |
Animal/Disease Models:CT26 colon cancer mouse [1]
Doses: 10 mg/kg single dose Route of Administration: i.p Experimental Results: Single-agent treatment reduced tumor weight by 30.8% and tumor volume by 32.1%. Co-administration with doxorubicin (2.5 mg/kg) produced more significant tumor inhibitory activity, with a TGI of 50.2%. No significant weight loss or deaths were observed. |
| References |
| Molecular Formula |
C22H22N8O
|
|---|---|
| Molecular Weight |
414.46
|
| Appearance |
Typically exists as solid at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4128 mL | 12.0639 mL | 24.1278 mL | |
| 5 mM | 0.4826 mL | 2.4128 mL | 4.8256 mL | |
| 10 mM | 0.2413 mL | 1.2064 mL | 2.4128 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
